{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=16",
    "query": {
      "condition": "Advanced Small Intestine Cancer",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 371,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T22:31:55.569Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02262455",
      "title": "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "STM 434",
          "type": "DRUG"
        },
        {
          "name": "Liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santa Maria Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-10",
      "completion_date": "2017-01-13",
      "has_results": false,
      "last_update_posted_date": "2017-02-13",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02262455"
    },
    {
      "nct_id": "NCT07397338",
      "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors",
        "Non-small Cell Lung Cancer (NSCLC)",
        "NSCLC",
        "Colorectal Cancer (CRC)",
        "CRC"
      ],
      "interventions": [
        {
          "name": "Daraxonrasib",
          "type": "DRUG"
        },
        {
          "name": "Elironrasib",
          "type": "DRUG"
        },
        {
          "name": "Zoldonrasib",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)",
          "type": "DRUG"
        },
        {
          "name": "cetuximab (Cohort C2 Only)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)",
          "type": "DRUG"
        },
        {
          "name": "Daraxonrasib (Cohort B1 only)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2026-01-30",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Norwich, Connecticut • Saint Paul, Minnesota + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07397338"
    },
    {
      "nct_id": "NCT04868877",
      "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer Metastatic",
        "Gastric Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MCLA-129",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merus B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2021-04-28",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 4,
      "location_summary": "Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04868877"
    },
    {
      "nct_id": "NCT03953235",
      "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Solid Tumor",
        "Shared Neoantigen-Positive Solid Tumors"
      ],
      "interventions": [
        {
          "name": "GRT-C903",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GRT-R904",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gritstone bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2019-07-18",
      "completion_date": "2023-03-10",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03953235"
    },
    {
      "nct_id": "NCT05239143",
      "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Renal Cell Carcinoma",
        "Nasopharyngeal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "P-MUC1C-ALLO1 CAR-T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Poseida Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2022-02-15",
      "completion_date": "2039-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 14,
      "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05239143"
    },
    {
      "nct_id": "NCT06451497",
      "title": "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Pancreas Adenocarcinoma",
        "Biliary Tract Cancer",
        "Prostate Cancer",
        "Urothelial Carcinoma",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Diffuse Large B Cell Lymphoma",
        "Renal Cell Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "ZM008",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Zumutor Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-05-22",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin, TX 78758",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451497"
    },
    {
      "nct_id": "NCT04068896",
      "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Head Neck Squamous Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NGM120 30mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 30mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg Q3W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-10-16",
      "completion_date": "2024-01-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068896"
    },
    {
      "nct_id": "NCT05736731",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Solid Tumor",
        "Pancreatic Cancer",
        "Pancreatic Neoplasms",
        "Pancreas Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "NSCLC",
        "NSCLC, Recurrent",
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colorectal Cancer Metastatic",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "A2B530",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT-Onco with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-04-28",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05736731"
    },
    {
      "nct_id": "NCT07602842",
      "title": "A Study of IDP-001 in Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Head and Neck Squamous Cell Carcinoma",
        "Cutaneous Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma of the Cervix",
        "Non Squamous Non Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Esophagus",
        "Squamous Cell Carcinoma of the Anus",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "IDP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InduPro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2026-07-08",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07602842"
    },
    {
      "nct_id": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Malignant Fibrous Histiocytoma of Bone",
        "Desmoid Tumor",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 53,
      "start_date": "2007-04",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-10-30T22:31:55.569Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474994"
    }
  ]
}